Pragmatic Implementation Trial of a CF Primary Palliative Care Intervention
1 other identifier
interventional
643
1 country
5
Brief Summary
Five Cystic Fibrosis (CF) centers, key stakeholders, and a palliative care institute have collaborated to create a novel primary palliative care intervention for patients with CF, "Improving Life with CF: A Primary Palliative Care Partnership," and established the infrastructure and support necessary for a follow-on implementation study. This intervention provides a framework for a nationally generalizable model to improve best practices in generalist-level palliative care in CF. Objectives: Aim 1: Implement a primary palliative care intervention comprising screening-and-triage workflows, best practice treatment guides for high frequency problems, patient/family and provider education, and a quality improvement (QI) toolkit. Aim 2: Evaluate feasibility, uptake, and preliminary outcomes during a multisite pragmatic, implementation trial of the intervention at 5 diverse Cystic Fibrosis (CF) Centers. Subaim 2.1: Evaluate feasibility and uptake as measured by rates of screening and treatment delivery. Hypothesis 1: Related to feasibility and uptake of the intervention:
- 1.\> 80% of individuals with CF of all ages will receive an annual palliative care screening.
- 2.\> 25% of individuals with CF will receive a palliative care screening prompted by hospitalization, new diagnosis of CF-Related Diabetes, need for transplantation, or another disease- or treatment-specific trigger.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Jun 2021
Longer than P75 for not_applicable
5 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 7, 2021
CompletedFirst Posted
Study publicly available on registry
June 11, 2021
CompletedStudy Start
First participant enrolled
June 25, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 30, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
June 30, 2025
CompletedOctober 30, 2025
October 1, 2025
4 years
June 7, 2021
October 28, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Proportion of individuals with CF receiving annual palliative care screening
Evaluate uptake of annual palliative care needs assessment process across 5 CF centers
2 years
Secondary Outcomes (13)
Proportion of individuals with CF receiving triggered palliative care screening
2 years
Use of primary palliative care provider education materials
2 years
Integrated Palliative Care Outcome Scale (IPOS)
2 years
Memorial Symptom Assessment Scale-Cystic Fibrosis (MSAS-CF)
2 years
Cystic Fibrosis Questionnaire-Revised (CFQ-R)
2 years
- +8 more secondary outcomes
Study Arms (1)
Implementation of Primary Palliative Care Intervention in CF Centers
OTHERImplement a Primary Palliative Care intervention comprising screening-and-triage workflows, best practice treatment guides for high frequency problems, patient/family and provider education, and a quality improvement (QI) toolkit in 5 CF centers.
Interventions
Individuals with CF ages 12 years and above will complete an annual palliative care needs assessment with the CF care team using the IPOS (Integrated Palliative Care Outcome Scale). Individuals with CF under 12 years of age will complete an annual palliative care needs assessment with the CF care team using IPOS as a conversation guide. Caregivers of Individuals with CF of all ages will be offered the BASC (Brief Assessment Scale for Caregivers). In addition to annual needs assessment, palliative care needs assessment will take place when triggered by changes in disease status, such as hospitalization, new diagnosis of CF related Diabetes or referral to transplant.
Eligibility Criteria
You may not qualify if:
- Have a diagnosis of CF.
- Receive treatment at one of the participating CF Care Centers in the study.
- Age ≥ 12 years.
- For patients age 12-17 years, willingness and ability to provide implied informed consent by a parent or legal guardian for the patient's participation in the study, with child's implied assent, AND willingness and ability to provide consent by the parent or legal guardian for the parent's or guardian's participation in the caregiver assessment, for proxy completion of selected study measures.
- For patients age \>18 years, willingness and ability to provide implied informed consent for participation in the study.
- Willingness to complete questionnaires two times.
- English or Spanish as the primary language.
- In order to ensure generalizability of the intervention, participants will not be excluded from the study for any of the following reasons:
- Extent of CF disease severity or lung/liver transplant status.
- Current use of CFTR modulators or other medical, psychological, or complementary therapies.
- Concomitant participation in another clinical research study.
- Lack of a participating caregiver for patients age \> 18 years.
- Are an identified caregiver of a patient with CF of any age, who receives treatment at one of the participating CF Care Centers in the study.
- For patients age \< 18 years, the caregiver will be a parent or legal guardian.
- For patients age ≥ 18 years, the caregiver will be chosen by the patient (e.g., parent, spouse, partner, other relative or friend).
- +5 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Massachusetts General Hospitallead
- MJHS Institute for Innovation in Palliative Carecollaborator
- Emory Universitycollaborator
- Stony Brook Universitycollaborator
- Feinstein Institute for Medical Researchcollaborator
Study Sites (5)
Emory University
Atlanta, Georgia, 30322, United States
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
Northwell Health-Lenox Hill
New York, New York, 10075, United States
Northwell Health
New York, New York, 11040, United States
Stonybrook University
New York, New York, 11794, United States
Related Publications (35)
Dhingra L, Walker P, Berdella M, Plachta A, Chen J, Fresenius A, Balzano J, Barrett M, Bookbinder M, Wilder K, Glajchen M, Langfelder-Schwind E, Portenoy RK. Addressing the burden of illness in adults with cystic fibrosis with screening and triage: An early intervention model of palliative care. J Cyst Fibros. 2020 Mar;19(2):262-270. doi: 10.1016/j.jcf.2019.08.009. Epub 2019 Aug 27.
PMID: 31471264BACKGROUNDDellon EP, Goggin J, Chen E, Sabadosa K, Hempstead SE, Faro A, Homa K. Defining palliative care in cystic fibrosis: A Delphi study. J Cyst Fibros. 2018 May;17(3):416-421. doi: 10.1016/j.jcf.2017.10.011. Epub 2017 Oct 31.
PMID: 29097163BACKGROUNDQuill TE, Abernethy AP. Generalist plus specialist palliative care--creating a more sustainable model. N Engl J Med. 2013 Mar 28;368(13):1173-5. doi: 10.1056/NEJMp1215620. Epub 2013 Mar 6. No abstract available.
PMID: 23465068BACKGROUNDKavalieratos D, Georgiopoulos AM, Dhingra L, Basile MJ, Rabinowitz E, Hempstead SE, Faro A, Dellon EP. Models of Palliative Care Delivery for Individuals with Cystic Fibrosis: Cystic Fibrosis Foundation Evidence-Informed Consensus Guidelines. J Palliat Med. 2021 Jan;24(1):18-30. doi: 10.1089/jpm.2020.0311. Epub 2020 Sep 16.
PMID: 32936045BACKGROUNDGeorgiopoulos AM, Friedman D, Porter EA, Krasner A, Kakarala SP, Glaeser BK, Napoleon SC, Wozniak J. Screening for ADHD in adults with cystic fibrosis: Prevalence, health-related quality of life, and adherence. J Cyst Fibros. 2018 Mar;17(2):276-280. doi: 10.1016/j.jcf.2017.08.011. Epub 2017 Sep 1.
PMID: 28867260BACKGROUNDQuittner AL, Goldbeck L, Abbott J, Duff A, Lambrecht P, Sole A, Tibosch MM, Bergsten Brucefors A, Yuksel H, Catastini P, Blackwell L, Barker D. Prevalence of depression and anxiety in patients with cystic fibrosis and parent caregivers: results of The International Depression Epidemiological Study across nine countries. Thorax. 2014 Dec;69(12):1090-7. doi: 10.1136/thoraxjnl-2014-205983. Epub 2014 Sep 21.
PMID: 25246663BACKGROUNDLinnemann RW, O'Malley PJ, Friedman D, Georgiopoulos AM, Buxton D, Altstein LL, Sicilian L, Lapey A, Sawicki GS, Moskowitz SM. Development and evaluation of a palliative care curriculum for cystic fibrosis healthcare providers. J Cyst Fibros. 2016 Jan;15(1):90-5. doi: 10.1016/j.jcf.2015.03.005. Epub 2015 Mar 25.
PMID: 25817162BACKGROUNDFriedman D, Linnemann RW, Altstein LL, Islam S, Bach KT, Lamb C, Volpe J, Doolittle C, St John A, O'Malley PJ, Sawicki GS, Georgiopoulos AM, Yonker LM, Moskowitz SM. The CF-CARES primary palliative care model: A CF-specific structured assessment of symptoms, distress, and coping. J Cyst Fibros. 2018 Jan;17(1):71-77. doi: 10.1016/j.jcf.2017.02.011. Epub 2017 Mar 14.
PMID: 28302366BACKGROUNDFriedman D, Linnemann RW, Altstein LL, Georgiopoulos AM, Islam S, Bach KT, St John A, Fracchia MS, Neuringer I, Lapey A, Sicilian L, Moskowitz SM, Yonker LM. Effects of a primary palliative care intervention on quality of life and mental health in cystic fibrosis. Pediatr Pulmonol. 2019 Jul;54(7):984-992. doi: 10.1002/ppul.24311. Epub 2019 Mar 10.
PMID: 30854795BACKGROUNDLinnemann RW, Friedman D, Altstein LL, Islam S, Bach KT, Georgiopoulos AM, Moskowitz SM, Yonker LM. Advance Care Planning Experiences and Preferences among People with Cystic Fibrosis. J Palliat Med. 2019 Feb;22(2):138-144. doi: 10.1089/jpm.2018.0262. Epub 2018 Oct 18.
PMID: 30335569BACKGROUNDBalzano J, Fresenius A, Walker P, Berdella M, Portenoy RK, Bookbinder M, Glajchen M, Plachta A, Langfelder-Schwind E, Chen J, Dhingra L. Web-based symptom screening in cystic fibrosis patients: A feasibility study. J Cyst Fibros. 2016 Jan;15(1):102-8. doi: 10.1016/j.jcf.2015.11.001. Epub 2015 Nov 21.
PMID: 26610859BACKGROUNDWojtaszczyk A, Glajchen M, Portenoy RK, Berdella M, Walker P, Barrett M, Chen J, Plachta A, Balzano J, Fresenius A, Wilder K, Langfelder-Schwind E, Dhingra L. Trajectories of caregiver burden in families of adult cystic fibrosis patients. Palliat Support Care. 2018 Dec;16(6):732-740. doi: 10.1017/S1478951517000918. Epub 2017 Oct 17.
PMID: 29037271BACKGROUNDAhluwalia SC, Chen C, Raaen L, Motala A, Walling AM, Chamberlin M, O'Hanlon C, Larkin J, Lorenz K, Akinniranye O, Hempel S. A Systematic Review in Support of the National Consensus Project Clinical Practice Guidelines for Quality Palliative Care, Fourth Edition. J Pain Symptom Manage. 2018 Dec;56(6):831-870. doi: 10.1016/j.jpainsymman.2018.09.008. Epub 2018 Oct 31.
PMID: 30391049BACKGROUNDBasile M, Jojan L, Hobler MR, Dellon EP, Georgiopoulos AM, Goggin JL, Chen E, Goss CH, Hempstead SE, Faro A, Kavalieratos D. Assessing Practices, Beliefs, and Attitudes about Palliative Care among People with Cystic Fibrosis, Their Caregivers, and Clinicians: Results of a Content Analysis. J Palliat Med. 2021 Nov;24(11):1650-1656. doi: 10.1089/jpm.2020.0725. Epub 2021 Apr 20.
PMID: 33885355BACKGROUNDCollins ES, Witt J, Bausewein C, Daveson BA, Higginson IJ, Murtagh FE. A Systematic Review of the Use of the Palliative Care Outcome Scale and the Support Team Assessment Schedule in Palliative Care. J Pain Symptom Manage. 2015 Dec;50(6):842-53.e19. doi: 10.1016/j.jpainsymman.2015.07.015. Epub 2015 Aug 31.
PMID: 26335764BACKGROUNDSawicki GS, Sellers DE, Robinson WM. Self-reported physical and psychological symptom burden in adults with cystic fibrosis. J Pain Symptom Manage. 2008 Apr;35(4):372-80. doi: 10.1016/j.jpainsymman.2007.06.005. Epub 2008 Jan 22.
PMID: 18215497BACKGROUNDCollins JJ, Devine TD, Dick GS, Johnson EA, Kilham HA, Pinkerton CR, Stevens MM, Thaler HT, Portenoy RK. The measurement of symptoms in young children with cancer: the validation of the Memorial Symptom Assessment Scale in children aged 7-12. J Pain Symptom Manage. 2002 Jan;23(1):10-6. doi: 10.1016/s0885-3924(01)00375-x.
PMID: 11779663BACKGROUNDCollins JJ, Byrnes ME, Dunkel IJ, Lapin J, Nadel T, Thaler HT, Polyak T, Rapkin B, Portenoy RK. The measurement of symptoms in children with cancer. J Pain Symptom Manage. 2000 May;19(5):363-77. doi: 10.1016/s0885-3924(00)00127-5.
PMID: 10869877BACKGROUNDModi AC, Quittner AL. Validation of a disease-specific measure of health-related quality of life for children with cystic fibrosis. J Pediatr Psychol. 2003 Dec;28(8):535-45. doi: 10.1093/jpepsy/jsg044.
PMID: 14602844BACKGROUNDQuittner AL, Sawicki GS, McMullen A, Rasouliyan L, Pasta DJ, Yegin A, Konstan MW. Erratum to: Psychometric evaluation of the Cystic Fibrosis Questionnaire-Revised in a national, US sample. Qual Life Res. 2012 Sep;21(7):1279-90. doi: 10.1007/s11136-011-0091-5. Epub 2012 Jan 13.
PMID: 22240933BACKGROUNDQuittner AL, Schechter MS, Rasouliyan L, Haselkorn T, Pasta DJ, Wagener JS. Impact of socioeconomic status, race, and ethnicity on quality of life in patients with cystic fibrosis in the United States. Chest. 2010 Mar;137(3):642-50. doi: 10.1378/chest.09-0345. Epub 2009 Oct 9.
PMID: 19820076BACKGROUNDQuittner AL, Modi AC, Wainwright C, Otto K, Kirihara J, Montgomery AB. Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Chest. 2009 Jun;135(6):1610-1618. doi: 10.1378/chest.08-1190. Epub 2009 May 15.
PMID: 19447923BACKGROUNDAlpern AN, Brumback LC, Ratjen F, Rosenfeld M, Davis SD, Quittner AL. Initial evaluation of the Parent Cystic Fibrosis Questionnaire--Revised (CFQ-R) in infants and young children. J Cyst Fibros. 2015 May;14(3):403-11. doi: 10.1016/j.jcf.2014.11.002. Epub 2014 Nov 28.
PMID: 25443473BACKGROUNDElkins MR, Robinson M, Rose BR, Harbour C, Moriarty CP, Marks GB, Belousova EG, Xuan W, Bye PT; National Hypertonic Saline in Cystic Fibrosis (NHSCF) Study Group. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med. 2006 Jan 19;354(3):229-40. doi: 10.1056/NEJMoa043900.
PMID: 16421364BACKGROUNDKroenke K, Strine TW, Spitzer RL, Williams JB, Berry JT, Mokdad AH. The PHQ-8 as a measure of current depression in the general population. J Affect Disord. 2009 Apr;114(1-3):163-73. doi: 10.1016/j.jad.2008.06.026. Epub 2008 Aug 27.
PMID: 18752852BACKGROUNDSpitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire. JAMA. 1999 Nov 10;282(18):1737-44. doi: 10.1001/jama.282.18.1737.
PMID: 10568646BACKGROUNDLowe B, Unutzer J, Callahan CM, Perkins AJ, Kroenke K. Monitoring depression treatment outcomes with the patient health questionnaire-9. Med Care. 2004 Dec;42(12):1194-201. doi: 10.1097/00005650-200412000-00006.
PMID: 15550799BACKGROUNDSpitzer RL, Kroenke K, Williams JB, Lowe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006 May 22;166(10):1092-7. doi: 10.1001/archinte.166.10.1092.
PMID: 16717171BACKGROUNDPilkonis PA, Yu L, Colditz J, Dodds N, Johnston KL, Maihoefer C, Stover AM, Daley DC, McCarty D. Item banks for alcohol use from the Patient-Reported Outcomes Measurement Information System (PROMIS): use, consequences, and expectancies. Drug Alcohol Depend. 2013 Jun 1;130(1-3):167-77. doi: 10.1016/j.drugalcdep.2012.11.002. Epub 2012 Dec 1.
PMID: 23206377BACKGROUNDCohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. J Health Soc Behav. 1983 Dec;24(4):385-96. No abstract available.
PMID: 6668417BACKGROUNDGolden-Kreutz DM, Browne MW, Frierson GM, Andersen BL. Assessing stress in cancer patients: a second-order factor analysis model for the Perceived Stress Scale. Assessment. 2004 Sep;11(3):216-23. doi: 10.1177/1073191104267398.
PMID: 15358877BACKGROUNDIrwin DE, Gross HE, Stucky BD, Thissen D, DeWitt EM, Lai JS, Amtmann D, Khastou L, Varni JW, DeWalt DA. Development of six PROMIS pediatrics proxy-report item banks. Health Qual Life Outcomes. 2012 Feb 22;10:22. doi: 10.1186/1477-7525-10-22.
PMID: 22357192BACKGROUNDScott EL, Foxen-Craft E, Caird M, Philliben R, deSebour T, Currier E, Voepel-Lewis T. Parental Proxy PROMIS Pain Interference Scores are Only Modestly Concordant With Their Child's Scores: An Effect of Child Catastrophizing. Clin J Pain. 2020 Jan;36(1):1-7. doi: 10.1097/AJP.0000000000000772.
PMID: 31599745BACKGROUNDGlajchen M, Kornblith A, Homel P, Fraidin L, Mauskop A, Portenoy RK. Development of a brief assessment scale for caregivers of the medically ill. J Pain Symptom Manage. 2005 Mar;29(3):245-54. doi: 10.1016/j.jpainsymman.2004.06.017.
PMID: 15781175BACKGROUNDHays RD, Bjorner JB, Revicki DA, Spritzer KL, Cella D. Development of physical and mental health summary scores from the patient-reported outcomes measurement information system (PROMIS) global items. Qual Life Res. 2009 Sep;18(7):873-80. doi: 10.1007/s11136-009-9496-9. Epub 2009 Jun 19.
PMID: 19543809BACKGROUND
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Anna M Georgiopoulos, MD
Massachusetts General Hospital (MGH)
- PRINCIPAL INVESTIGATOR
Lara Dhingra, PhD
MJHS Institute for Innovation in Palliative Care (MJHS Institute)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- HEALTH SERVICES RESEARCH
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
June 7, 2021
First Posted
June 11, 2021
Study Start
June 25, 2021
Primary Completion
June 30, 2025
Study Completion
June 30, 2025
Last Updated
October 30, 2025
Record last verified: 2025-10
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP
- Time Frame
- Beginning 9 months and ending 36 months after study publication.
- Access Criteria
- Investigators submitting a methodologically sound proposal, as determined by the study's lead investigators. Proposals should be directed to ldhingra@mjhs.org.
The dataset for this study, including the study protocol, statistical analysis plan, and individual de-identified participant data underlying the results reported in publication (text, tables, figures and appendices), will be made accessible four months from initial request to investigators who provide a methodologically sound proposal, as determined by the study's lead investigators. The dataset will be provided after its de-identification, in compliance with relevant regulatory and privacy laws, data safeguards, and requirements for patient consent and anonymization.